Cost-effectiveness analysis of tissue plasminogen activator in acute ischemic stroke in Iran.
CONCLUSIONS: The balance of hospitalization and rehabilitation costs and QALYs support the conclusion that treatment with intravenous tPA in the 4.5 hour time window is cost-effective from the perspectives of third party payer and inclusion of tPA in the insurance benefit package is reasonable.
PMID: 29105528 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Economics | Health Management | Insurance | Iran Health | Ischemic Stroke | Middle East Health | Rehabilitation | Stroke | Study